Welcome to our dedicated page for Cellectar Biosciences news (Ticker: CLRB), a resource for investors and traders seeking the latest updates and insights on Cellectar Biosciences stock.
Cellectar Biosciences, Inc. (NASDAQ: CLRB) is a late-stage clinical radiopharmaceutical company developing targeted cancer drugs based on its proprietary Phospholipid Drug Conjugate (PDC) platform. The CLRB news feed on Stock Titan aggregates company announcements, scientific presentations and regulatory updates that reflect the progress of this oncology pipeline.
Investors and researchers following Cellectar’s news can track developments around its lead asset, iopofosine I 131, including data from the CLOVER WaM Phase 2b study in Waldenstrom’s macroglobulinemia, the CLOVER‑2 pediatric high‑grade glioma program, and investigator‑initiated work in head and neck cancer. News items also cover FDA designations such as Breakthrough Therapy, Orphan Drug, Rare Pediatric Disease and Fast Track, as well as EMA PRIME and orphan designations and feedback from the EMA’s Scientific Advice Working Party on a potential Conditional Marketing Authorization filing in Europe.
The CLRB news stream highlights updates on Auger‑ and alpha‑emitting candidates CLR 121125 (CLR 125) and CLR 121225 (CLR 225), including preclinical data in triple‑negative breast cancer and pancreatic ductal adenocarcinoma, clinical trial planning, and supply agreements for key radioisotopes like actinium‑225 and astatine‑211. Financial results, capital raises, warrant transactions, and reverse stock split actions reported in SEC‑linked press releases provide additional context on how the company funds its development plans.
By monitoring this page, users can review historical and ongoing disclosures about Cellectar’s clinical results, regulatory interactions, partnerships and financing activities, all drawn from company-issued news and related filings.
Cellectar Biosciences, Inc. (NASDAQ: CLRB) reported its 2021 financial results, showing a net loss of $24.1 million, or $0.43 per share, up from a $15.1 million loss in 2020. The company highlighted data from its Phase 2 CLOVER-1 study of iopofosine I-131, revealing a 45.5% overall response rate in multiple myeloma patients. Notable progress was made in a Phase 1 study involving children with relapsed high-grade gliomas, with positive tumor response and a recommendation to proceed with higher dosing. Cellectar maintains a strong balance sheet with $35.7 million in cash to fund operations into 2023.
Cellectar Biosciences (NASDAQ: CLRB) announced its participation in upcoming investor conferences, including the Roth Capital Partners 34th Annual Conference on March 15, 2022, and the Oppenheimer 32nd Annual Healthcare Conference on March 16, 2022. Both events will feature fireside chats and opportunities for 1x1 meetings with investors. Cellectar is focused on developing innovative cancer treatments using its proprietary Phospholipid Drug Conjugate platform, with ongoing studies on its lead asset, iopofosine, targeting various cancer types, including Waldenstrom's macroglobulinemia and pediatric cancers.
Cellectar Biosciences (NASDAQ: CLRB) has appointed Chad Kolean as Chief Financial Officer and promoted Jarrod Longcor to Chief Operating Officer. Kolean returns after a successful tenure at other companies, aiming to leverage his extensive industry experience. Longcor, with six years at Cellectar, will oversee operations and strategic growth efforts as the company prepares for a potential NDA filing for its drug targeting Waldenstrom’s macroglobulinemia. The company also plans a pivotal trial assessment of its lead compound, iopofosine I-131, in the near future.
Cellectar Biosciences (NASDAQ: CLRB) announced participation in a fireside chat at the H.C. Wainwright Bioconnect conference, scheduled for January 10-13, 2022. CEO Jim Caruso and CBO Jarrod Longcor will discuss company updates, with the chat available on-demand from 7:00 am ET on January 10.
Cellectar is focused on developing targeted cancer therapies, leveraging its proprietary Phospholipid Drug Conjugate™ (PDC) platform. The pipeline includes iopofosine for relapsed or refractory cancers, currently in pivotal studies.
Cellectar Biosciences (NASDAQ: CLRB) presented promising data from 11 patients in its ongoing Phase 2 CLOVER-1 study of iopofosine I-131 for treating refractory multiple myeloma at the ASH Annual Meeting. The trial showed an overall response rate (ORR) of 45.5%, with a clinical benefit rate (CBR) of 72.7% and a disease control rate (DCR) of 100%. In a subgroup of quad/penta drug refractory patients, the ORR reached 80%.
Despite these positive results, cytopenias were noted as the primary adverse events. The company anticipates sharing further data as the study progresses.
On December 8, 2021, Cellectar Biosciences (NASDAQ: CLRB) announced a poster presentation at the ASH Annual Meeting, showcasing data from the ongoing Phase 2 CLOVER-1 study of iopofosine I-131. The study focuses on eleven patients with triple-class refractory multiple myeloma, highlighting preliminary efficacy and safety results. The poster session will occur on December 11, 2021. Iopofosine is designed for targeted cancer treatment and is undergoing multiple clinical studies, including a pivotal trial for Waldenstrom's macroglobulinemia.
Cellectar Biosciences (CLRB) announced positive results from a Phase 1 study of iopofosine I-131 for treating pediatric relapsed cancers, specifically high-grade gliomas and soft tissue sarcomas. The study showed promising tumor responses, with patients experiencing over 5 months of progression-free survival, almost double the historical norm of 2-3 months. The Data Monitoring Committee has approved dose escalations, suggesting the treatment is safe and tolerable. Cellectar plans to engage with the FDA on potential next steps for regulatory approval.
Cellectar Biosciences (NASDAQ: CLRB) reported Q3 financial results for the period ending September 30, 2021. The company completed Part A of a safety study for iopofosine in combination with external beam radiation for head and neck cancer. Preliminary data indicates safety and tolerability. They secured a $2 million NIH Phase II SBIR grant to support iopofosine’s pivotal study in Waldenstrom’s macroglobulinemia. Cash reserves stood at $40.3 million, but the company posted a net loss of $5.8 million for Q3, widening from a $3.9 million loss in 2020.
Cellectar Biosciences (NASDAQ: CLRB) announced Dr. Laurence Reilly as interim chief medical officer, succeeding Dr. John Friend, who departs for personal reasons. Dr. Reilly brings extensive experience in hematological oncology and is expected to lead Cellectar's clinical development programs, including the pivotal trial for iopofosine I-131 in treating Waldenstrom’s macroglobulinemia. The company remains financially stable and aims to advance its cancer treatment pipeline through ongoing trials and collaborations.
Cellectar Biosciences (NASDAQ: CLRB) has announced a collaboration with BBK Worldwide to enhance patient support services for participants in its clinical studies. This initiative aims to provide comprehensive concierge services, including transportation and assistance with reimbursement for cancer patients. The focal point of this collaboration is the ongoing pivotal study of iopofosine I-131 for Waldenstrom's macroglobulinemia. Cellectar is also engaged in additional clinical studies involving iopofosine for other hematologic malignancies.